Discover how the HEK293-derived Pro10™ cell line accelerates AAV vector production. This whitepaper explores a scalable, animal component-free platform that reduces process development time and costs, meeting growing clinical and commercial demands for gene therapies.
Resources
February 06, 2023
White paper: A proprietary mammalian suspension technology for scalable rAAV production: The Pro10™ cell line
Explore more

News
AskBio Announces 6 Presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting
One oral presentation and five poster presentations will highlight exciting progress in AskBio’s pipeline and advancements in the company’s manufacturing technologies Research Triangle Park, N.C.– OCTOBER 2, 2025 – AskBio Inc. (AskBio), a gene...
READ MORE
October 02, 2025
Insights
Harnessing AI for Faster and More Efficient Development & Manufacturing of Life-Changing Gene Therapies
Authors: María Iglesias, Head of Digital & IT Jens Keune, Data Science & Digital Product Manager Abstract As the biopharmaceutical landscape evolves, the integration of Artificial Intelligence (AI) into gene therapy manufacturing is increasingly...
READ MORE
July 28, 2025

Resources
Webinar: Outsourced Pharma Capacity Update July 2025
“May you live in interesting times.” Viralgen Chief Commercial Officer Andy Holt invokes that apocryphal “half-blessing, half-curse” as he opens his recent appearance on Outsourced Pharma Capacity Update. Andy identifies some of the key dynamics...
READ MORE
July 17, 2025